Noema Pharma Raises CHF 130 Million in Series B Extension to Advance Breakthrough CNS Treatments Noema Pharma, a clinical-stage biotech company focused on developing innovative treatments for central nervous system (CNS) disorders, has successfully closed an extension of its Series B financing ro...

www.linkedin.com/pulse/noema-...

Noema Pharma Raises CHF 130 Million in Series B Extension to Advance Breakthrough CNS Treatments

kstrategyand.com/pharma-news

#NoemaPharma #CNSDisorders #Neuroscience #SeriesBFunding #EQTLifeSciences #Neurotherapeutics #Humanteconomy #Humantec #KStrategyand